



UNIVERSITÀ DEGLI STUDI DI ROMA

"TOR VERGATA"

FACOLTA' DI MEDICINA E CHIRURGIA

DOTTORATO DI RICERCA IN

IMMUNOLOGIA E MICROBIOLOGIA MEDICA

XX Ciclo

**Design of Human Single Chain Fragments for Antibody Direct
Enzyme Prodrug Therapy (ADEPT)**

SILVIA ZAMBONI

Docente Guida: *Prof. Maurizio Cianfriglia*

Coordinatore: *Prof. Carlo Federico Perno*

TABLE OF CONTENTS

ABSTRACT.....	2
INTRODUCTION.....	3
1 ANTIBODIES.....	3
<i>1.1 Antibodies as new therapeutic proteins.....</i>	<i>3</i>
<i>1.2 Antibodies structure an function.....</i>	<i>4</i>
<i>1.3 Conventional and Recombinant Monoclonal Antibodies.....</i>	<i>7</i>
<i>1.4 Antibody Phage Display Technology.....</i>	<i>13</i>
<i>1.4.1 Phage Display Technology.....</i>	<i>13</i>
<i>1.4.2 Phage Display of Antibody Fragments.....</i>	<i>16</i>
<i>1.4.3 Antibody Repertoires.....</i>	<i>17</i>
<i>1.5 Engineered Antibody Fragments</i>	<i>22</i>
2 IMMUNOTHERAPY.....	27
<i>2.1 Enhancing Effector Functions.....</i>	<i>29</i>
<i>2.2 Direct Arming.....</i>	<i>30</i>
<i>2.3 Indirect Arming.....</i>	<i>33</i>
<i>2.4 Pretargeting Prodrug.....</i>	<i>34</i>
3 ADEPT (Antibody Direct Enzyme Prodrug Therapy)	35
<i>3.1 Enzyme in ADEPT.....</i>	<i>37</i>
<i>3.2 Antibodies in ADEPT.....</i>	<i>38</i>

3.3 Prodrugs in ADEPT.....	38
3.4 Cytosine Deaminase.....	39
3.5 5-Fluorouracil.....	41
4 CARCINOEMBRYONIC ANTIGEN (CEA)	42
4.1 CEA structure.....	42
4.2 CEA and CEA family genes.....	44
4.3 CEA as tumor marker.....	47
MATERIALS AND METHODS.....	51
<i>Bacterial Strains.....</i>	51
<i>Cell lines</i>	51
<i>Antibodies and reagents.....</i>	51
<i>Primers.....</i>	51
<i>Genetic engineered constructs.....</i>	52
<i>Expression and Purification ¹.....</i>	53
<i>SDS PAGE and WB analysis ¹.....</i>	54
<i>ELISA ¹.....</i>	54
<i>CEA binding specificity of the scFvE8:yCD.....</i>	55
<i>Functional Assay of the scFvE8:yCD on cells.....</i>	56
<i>Vector construction.....</i>	57
<i>Expression and Purification ²</i>	57
<i>NMR.....</i>	58

<i>ETH-2 library</i>	58
<i>Selection of yCD protein specific antibody from ETH-2 library</i>	59
<i>ELISA</i> ²	59
<i>DNA characterization and sequencing</i>	60
<i>Soluble scFv purification</i>	60
<i>SDS PAGE and WB analysis</i> ²	61
<i>Determination of yCD activity</i>	61
<i>Cytotoxic assay</i>	62
RESULTS	64
<i>Genetic engineering of the scFv antibodies for ADEPT</i>	64
<i>The antigen specificity of the engineered fusion proteins</i>	67
<i>Functional assay of the scFvE8:yCD</i>	69
<i>Construction of scFv specific to yCD</i>	71
<i>Expression and purification of yCD protein</i>	72
<i>Selection and characterization of scFvH5 antibody specific to yCD</i>	73
<i>Determination of yCD activity</i>	75
<i>Cytotoxic assay</i>	77
DISCUSSION	78
REFERENCES	82